Trending Now
Twitter (NYSE:TWTR) could be Wall Street’s top stock and here’s why
The futures are basically flat this morning. Trump was impeached yesterday so we’ll see if that has any impact at all today. ...
DIH Holding US, Inc. (DHAI): Pioneering Rehabilitation with Cutting-Edge Technology
Let’s talk about something truly inspiring: the future of rehabilitation. On December 23, 2024, DIH Holding US, Inc. (NASDAQ: DHAI) announced...
Predictive Oncology Inc. (Nasdaq: POAI): A Transformative Acquisition by Renovaro Inc.
The biotechnological domain is currently abuzz with developments surrounding the acquisition of Predictive Oncology Inc. (Nasdaq: POAI) by Renovaro Inc. (Nasdaq: RENB)....
Popular News
Onconova Therapeutics Inc. (NASDAQ: ONTX) Releases Safety And Efficacy Data of...
Onconova Therapeutics Inc. (NASDAQ: ONTX) has releases interim efficacy and safety data from the investigator-initiated Phase 1/2, a study of oral rigosertib combination with...
MAKE IT MODERN
LATEST REVIEWS
Data from an Ongoing Phase II Basket Trial of neratinib in...
Results from the Phase II SUMMIT study evaluating the safety and efficacy of neratinib in HER2-mutated cancers have been published. According to Puma Biotechnology...
MAKE IT MODERN
PERFORMANCE TRAINING
BridgeBio Pharma Inc. (NASDAQ: BBIO) Doses First Patient in Phase 1/2 Adventure study of...
BridgeBio Pharma Inc. (NASDAQ: BBIO) has announced the dosing of the first patient in the Phase 1/2 ADventure clinical study of BBP-831, an experimental...
BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX) Announce Expanded Access For Berotralstat In HAE Patients And Findings...
BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX) established expanded access program (EAP) for its investigational drug berotralsat in the treatment of hereditary angioedema (HAE)patients in the US.
Berotralstat...
IPO’s for today: Indonesian Energy Corp (NYSE:INDO), Monopar Therapeutics (TLV:MNPR)
Indonesian Energy Corp (INDO) - This IPO owns 8 wells in Indonesia and is an oil and gas company. They are profitable...
Arbutus Biopharma Corporation (NASDAQ: ABUS) Announces Interim Phase 1a/1b Clinical Study Results of AB-836
Arbutus Biopharma Corporation (NASDAQ: ABUS) has announced interim data from the ongoing Phase 1a/1b clinical study showing that its next-gen capsid inhibitor, AB-836 is...
Monopar Therapeutics Inc. (NASDAQ: MNPR) Doses First Advanced Soft Tissues Sarcoma Patient In Study...
Monopar Therapeutics Inc. (NASDAQ: MNPR) has doses the first patient in the dose-escalation, open-label phase 1b clinical study evaluating camsirubicin in advanced soft tissues...
MAKE IT MODERN
